Categories
Prostate cancer

Prostate cancer in transgender women: considerations for screening, diagnosis and management

  • Cooper K, Russell A, Mandy W, Butler C. The phenomenology of gender dysphoria in adults: a systematic review and meta-synthesis. Clin Psychol Rev. 2020;80:101875.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Baker KE. Findings from the behavioral risk factor surveillance system on health-related quality of life among US transgender adults, 2014-2017. JAMA Intern Med. 2019;179:1141–4.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Flores AR, Brown TN, Herman J. Race and ethnicity of adults who identify as transgender in the United States. CA: Williams Institute, UCLA School of Law Los Angeles; 2016.

  • James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi, M. The Report of the 2015 U.S. Transgender Survey. National Center for Transgender Equality, Washington, DC. 2016.

  • Badgett MV, Choi SK, Wilson BDM. LGBT poverty in the United States: a study of differences between sexual orientation and gender identity groups (2019). https://williamsinstitute.law.ucla.edu/wp-content/uploads/National-LGBT-Poverty-Oct-2019.pdf.

  • Jackson SS, Han X, Mao Z, Nogueira L, Suneja G, Jemal A, et al. Cancer stage, treatment, and survival among transgender patients in the United States. J Natl Cancer Inst. 2021;113:1221–7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rosser BRS, Capistrant B, Torres B, Konety B, Merengwa E, Mitteldorf D, et al. The effects of radical prostatectomy on gay and bisexual men’s mental health, sexual identity and relationships: qualitative results from the restore study. Sex Relatsh Ther. 2016;31:446–61.

    Article 

    Google Scholar
     

  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA: A Cancer J Clin. 2021;71:7–33.


    Google Scholar
     

  • Viale PH. The American Cancer Society’s facts & figures: 2020 edition. J Adv Pr Oncol. 2020;11:135–6.


    Google Scholar
     

  • American Cancer Society. Cancer Facts & Figures 2021. Atlanta: American Cancer Society. 2021. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf.

  • Pritzlaff M, Tian Y, Reineke P, Stuenkel AJ, Allen K, Gutierrez S, et al. Diagnosing hereditary cancer predisposition in men with prostate cancer. Genet Med. 2020;22:1517–23.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Thurston AV. Carcinoma of the prostate in a transsexual. Br J Urol. 1994;73:217.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • van Haarst EP, Newling DW, Gooren LJ, Asscheman H, Prenger DM. Metastatic prostatic carcinoma in a male-to-female transsexual. Br J Urol. 1998;81:776.

    Article 
    PubMed 

    Google Scholar
     

  • Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, et al. Prostate cancer in a transgender woman 41 years after initiation of feminization. J Am Med Assoc. 2006;296:2316–7.

    Article 
    CAS 

    Google Scholar
     

  • Dorff TB, Shazer RL, Nepomuceno EM, Tucker SJ. Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. Clin Genitourin Cancer. 2007;5:344–6.

    Article 
    PubMed 

    Google Scholar
     

  • Turo R, Jallad S, Prescott S, Cross WR. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. Can Urol Assoc J. 2013;7:E544–546.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ellent E, Matrana MR. Metastatic prostate cancer 35 years after sex reassignment surgery. Clin Genitourin Cancer. 2016;14:e207–209.

    Article 
    PubMed 

    Google Scholar
     

  • Deebel NA, Morin JP, Autorino R, Vince R, Grob B, Hampton LJ. Prostate cancer in transgender women: incidence, etiopathogenesis, and management challenges. Urology. 2017;110:166–71.

    Article 
    PubMed 

    Google Scholar
     

  • Sharif A, Malhotra NR, Acosta AM, Kajdacsy-Balla AA, Bosland M, Guzman G, et al. The development of prostate adenocarcinoma in a transgender male to female patient: could estrogen therapy have played a role? Prostate. 2017;77:824–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ingham MD, Lee RJ, MacDermed D, Olumi AF. Prostate cancer in transgender women. Urol Oncol. 2018;36:518–25.

    Article 
    PubMed 

    Google Scholar
     

  • Bertoncelli Tanaka M, Sahota K, Burn J, Falconer A, Winkler M, Ahmed HU, et al. Prostate cancer in transgender women: what does a urologist need to know? BJU Int. 2022;129:113–22.

  • Gooren L, Morgentaler A. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia. 2014;46:1156–60.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Silverberg MJ, Nash R, Becerra-Culqui TA, Cromwell L, Getahun D, Hunkeler E, et al. Cohort study of cancer risk among insured transgender people. Ann Epidemiol. 2017;27:499–501.

    Article 
    PubMed 

    Google Scholar
     

  • Nash R, Ward KC, Jemal A, Sandberg DE, Tangpricha V, Goodman M. Frequency and distribution of primary site among gender minority cancer patients: an analysis of U.S. national surveillance data. Cancer Epidemiol. 2018;54:1–6.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Braun H, Nash R, Tangpricha V, Brockman J, Ward K, Goodman M. Cancer in transgender people: evidence and methodological considerations. Epidemiol Rev. 2017;39:93–107.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • de Nie I, de Blok CJM, van der Sluis TM, Barbé E, Pigot GLS, Wiepjes CM, et al. Prostate cancer incidence under androgen deprivation: nationwide cohort study in trans women receiving hormone treatment. J Clin Endocrinol Metab. 2020;105:e3293–e3299.

    Article 
    PubMed Central 

    Google Scholar
     

  • Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race/ethnicity—United States, 2001–2017. Morbidity Mortal Wkly Rep. 2020;69:1473.

    Article 

    Google Scholar
     

  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.

    Article 
    PubMed 

    Google Scholar
     

  • Gooren L. Hormone treatment of the adult transsexual patient. Horm Res. 2005;64:31–36.

    CAS 
    PubMed 

    Google Scholar
     

  • Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88:3467–73.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Stroumsa D, Crissman HP, Dalton VK, Kolenic G, Richardson CR. Insurance coverage and use of hormones among transgender respondents to a national survey. Ann Fam Med. 2020;18:528.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168:9–12.

    Article 
    PubMed 

    Google Scholar
     

  • Tsukamoto S, Akaza H, Onozawa M, Shirai T, Ideyama Y. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer. 1998;82:531–7.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wibowo E, Schellhammer P, Wassersug RJ. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol. 2011;185:17–23.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Dal Pra A, Cury F, Souhami L. Combining radiation therapy and androgen deprivation for localized prostate cancer—a critical review. Curr Oncol. 2010;17:28–38.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Crowley F, Sterpi M, Buckley C, Margetich L, Handa S, Dovey Z. A review of the pathophysiological mechanisms underlying castration-resistant prostate cancer. Res Rep. Urol. 2021;13:457–72.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Citrin DL, Resnick MI, Guinan P, al-Bussam N, Scott M, Gau TC, et al. A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial. Prostate. 1991;18:139–46.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bosland MC. The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention. Rev Urol. 2005;7:S4–S10.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Nelles JL, Hu W-Y, Prins GS. Estrogen action and prostate cancer. Expert Rev Endocrinol Metab. 2011;6:437–51.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bosland MC. A perspective on the role of estrogen in hormone-induced prostate carcinogenesis. Cancer Lett. 2013;334:28–33.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kruithof-Dekker IG, Têtu B, Janssen PJ, Van der Kwast TH. Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy. J Urol. 1996;156:1194–7.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Lundon DJ, Boland A, Prencipe M, Hurley G, O’Neill A, Kay E, et al. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation. BMC Cancer. 2017;17:1–13.

    Article 

    Google Scholar
     

  • Takizawa I, Lawrence MG, Balanathan P, Rebello R, Pearson HB, Garg E, et al. Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Oncotarget. 2015;6:604–16.

    Article 
    PubMed 

    Google Scholar
     

  • Megas G, Chrisofos M, Anastasiou I, Tsitlidou A, Choreftaki T, Deliveliotis C. Estrogen receptor (alpha and beta) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population. Asian J Androl. 2015;17:98–105.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008;73:233–44.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Di Zazzo E, Galasso G, Giovannelli P, Di Donato M, Bilancio A, Perillo B, et al. Estrogen receptors in epithelial-mesenchymal transition of prostate cancer. Cancers. 2019;11:1418.

  • Landstrom M, Damber JE, Bergh A. Estrogen treatment postpones the castration-induced dedifferentiation of Dunning R3327-PAP prostatic adenocarcinoma. Prostate. 1994;25:10–18.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Langley RE, Gilbert DC, Duong T, Clarke NW, Nankivell M, Rosen SD, et al. Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised prostate adenocarcinoma transcutaneous hormone (PATCH) trial programme. Lancet. 2021;397:581–91.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Langley RE, Kynaston HG, Alhasso AA, Duong T, Paez EM, Jovic G, et al. A randomised comparison evaluating changes in bone mineral density in advanced prostate cancer: luteinising hormone-releasing hormone agonists versus transdermal oestradiol. Eur Urol. 2016;69:1016–25.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Geier R, Adler S, Rashid G, Klein A. The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells. Prostate. 2010;70:1307–12.

    CAS 
    PubMed 

    Google Scholar
     

  • Dobbs RW, Malhotra NR, Greenwald DT, Wang AY, Prins GS, Abern MR. Estrogens and prostate cancer. Prostate Cancer Prostatic Dis. 2019;22:185–94.

    Article 
    PubMed 

    Google Scholar
     

  • Manikandan R, Srirangam SJ, Pearson E, Brown SC, O’Reilly P, Collins GN. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. Urol Int. 2005;75:217–21.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. 1988;7:165–70.

  • Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet. 1967;124:1011–7.

  • Di Zazzo E, Galasso G, Giovannelli P, Di Donato M, Castoria G. Estrogens and their receptors in prostate cancer: therapeutic implications. Front Oncol. 2018;8:2.

  • Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho H-K, et al. A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin Cancer Res. 1999;5:2366–73.

    CAS 
    PubMed 

    Google Scholar
     

  • Stein S, Zoltick B, Peacock T, Holroyde C, Haller D, Armstead B, et al. Phase II trial of toremifene in androgen-independent prostate cancer: a Penn cancer clinical trials group trial. Am J Clin Oncol. 2001;24:283–5.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Fujimura T, Takahashi S, Kume H, Urano T, Takayama K, Yamada Y, et al. Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial. BMC Cancer. 2015;15:1–8.

    Article 

    Google Scholar
     

  • Ho TH, Nunez-Nateras R, Hou Y-X, Bryce AH, Northfelt DW, Dueck AC, et al. A study of combination bicalutamide and raloxifene for patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2017;15:196–202. e191

    Article 
    PubMed 

    Google Scholar
     

  • Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 2002;295:2465–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Martinkovich S, Shah D, Planey SL, Arnott JA. Selective estrogen receptor modulators: tissue specificity and clinical utility. Clin Inter Aging. 2014;9:1437–52.


    Google Scholar
     

  • Bosland MC, Huang J, Schlicht MJ, Enk E, Xie H, Kato I. Impact of 18-month soy protein supplementation on steroid hormones and serum biomarkers of angiogenesis, apoptosis, and the growth hormone/IGF-1 axis: results of a randomized, placebo-controlled trial in males following prostatectomy. Nutr Cancer. 2022;74:110–21.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bonkhoff H. Estrogen receptor signaling in prostate cancer: implications for carcinogenesis and tumor progression. Prostate. 2018;78:2–10.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6:76–85.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Koochekpour S. Androgen receptor signaling and mutations in prostate cancer. Asian J Androl. 2010;12:639.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pernigoni N, Zagato E, Calcinotto A, Troiani M, Mestre RP, Calì B, et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science. 2021;374:216–24.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Fixemer T, Remberger K, Bonkhoff H. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate. 2003;54:79–87.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol. 1999;155:641–7.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Progesterone receptor expression in human prostate cancer: correlation with tumor progression. Prostate. 2001;48:285–91.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Shaw GL, Whitaker H, Corcoran M, Dunning MJ, Luxton H, Kay J, et al. The early effects of rapid androgen deprivation on human prostate cancer. Eur Urol. 2016;70:214–8.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21:383–91.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Schröder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol. 2008;53:468–77.

    Article 
    PubMed 

    Google Scholar
     

  • Merriel SWD, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20:54.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Force USPST. Screening for prostate cancer: US preventive services task force recommendation statement. J Am Med Assoc. 2018;319:1901–13.

    Article 

    Google Scholar
     

  • Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:419–26.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–29.

    Article 
    PubMed 

    Google Scholar
     

  • Naji L, Randhawa H, Sohani Z, Dennis B, Lautenbach D, Kavanagh O, et al. Digital rectal examination for prostate cancer screening in primary care: a systematic review and meta-analysis. Ann Fam Med. 2018;16:149–54.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Butler SS, Muralidhar V, Zhao SG, Sanford NN, Franco I, Fullerton ZH, et al. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer. 2020;126:717–24.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Fleshner K, Carlsson SV, Roobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol. 2017;14:26–37.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Catalona William J, Richie Jerome P, Ahmann Frederick R, Hudson M’Liss A, Scardino Peter T, Flanigan Robert C, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283–90.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology. 1993;42:365–74.

    Article 
    PubMed 

    Google Scholar
     

  • Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ. Characteristics of prostate cancer detected by digital rectal examination only. Urology. 2007;70:1117–20.

    Article 
    PubMed 

    Google Scholar
     

  • Gosselaar C, Roobol MJ, Roemeling S, Schröder FH. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol. 2008;54:581–8.

    Article 
    PubMed 

    Google Scholar
     

  • Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2017;102:3869–903.

    Article 
    PubMed 

    Google Scholar
     

  • Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism. 2012;13:165–232.

    Article 

    Google Scholar
     

  • Weyers S, De Sutter P, Hoebeke S, Monstrey G, G TS, Verstraelen H, et al. Gynaecological aspects of the treatment and follow-up of transsexual men and women. Facts Views Vis Obgyn. 2010;2:35–54.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rastrelli G, Corona G, Vignozzi L, Maseroli E, Silverii A, Monami M, et al. Serum PSA as a predictor of testosterone deficiency. J Sex Med. 2013;10:2518–28.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Trum HW, Hoebeke P, Gooren LJ. Sex reassignment of transsexual people from a gynecologist’s and urologist’s perspective. Acta Obstet Gynecol Scand. 2015;94:563–7.

    Article 
    PubMed 

    Google Scholar
     

  • Ahmed HU, Bosaily AE-S, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–22.

    Article 
    PubMed 

    Google Scholar
     

  • Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019;4. https://doi.org/10.1002/14651858.CD012663.pub2.

  • Eldred-Evans D, Burak P, Connor MJ, Day E, Evans M, Fiorentino F, et al. Population-based prostate cancer screening with magnetic resonance imaging or ultrasonography: the IP1-PROSTAGRAM study. JAMA Oncol. 2021;7:395–402.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Stowell JT, Grimstad FW, Kirkpatrick DL, Brown ER, Santucci RA, Crane C, et al. Imaging findings in transgender patients after gender-affirming surgery. RadioGraphics. 2019;39:1368–92.

    Article 
    PubMed 

    Google Scholar
     

  • Jin B, Turner L, Walters WA, Handelsman DJ. The effects of chronic high dose androgen or estrogen treatment on the human prostate [corrected]. J Clin Endocrinol Metab. 1996;81:4290–5.

    CAS 
    PubMed 

    Google Scholar
     

  • Starobinets O, Kurhanewicz J, Noworolski SM. Improved multiparametric MRI discrimination between low-risk prostate cancer and benign tissues in a small cohort of 5α-reductase inhibitor treated individuals as compared with an untreated cohort. NMR Biomed. 2017;30:e3696.

  • Gormley GJ, Ng J, Cook T, Stoner E, Guess H, Walsh P. Effect of finasteride on prostate-specific antigen density. Urology. 1994;43:53–58.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Parsi M, Desai MH, Desai D, Singhal S, Khandwala PM, Potdar RR. PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer. Med Oncol. 2021;38:89.

    Article 
    PubMed 

    Google Scholar
     

  • Eder M, Schäfer M, Bauder-Wüst U, Hull WE, Wängler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • FDA approves first PSMA-targeted PET drug. J Nucl Med. 2021;62:11N. https://jnm.snmjournals.org/content/62/2/11N.2.long.

  • Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80:682–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Starobinets O, Kurhanewicz J, Noworolski SM. Improved multiparametric MRI discrimination between low-risk prostate cancer and benign tissues in a small cohort of 5alpha-reductase inhibitor treated individuals as compared with an untreated cohort. NMR Biomed. 2017;30:e3696.

  • Diao W, Cai H, Chen L, Jin X, Liao X, Jia Z. Recent advances in prostate-specific membrane antigen-based radiopharmaceuticals. Curr Top Med Chem. 2019;19:33–56.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Li JZ, Tu HYV, Avram R, Pinthus J, Bordeleau L, Hodgson N. Cancer prevention and screening in a BRCA2-positive male to female transgender patient. Breast J. 2018;24:1112–3.

    Article 
    PubMed 

    Google Scholar
     

  • Colebunders B, T’Sjoen G, Weyers S, Monstrey S. Hormonal and surgical treatment in trans-women with BRCA1 mutations: a controversial topic. J Sex Med. 2014;11:2496–9.

    Article 
    PubMed 

    Google Scholar
     

  • Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol. 2020;77:24–35.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Forbes C, Fayter D, de Kock S, Quek RG. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res. 2019;11:2321.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Clarke CN, Cortina CS, Fayanju OM, Dossett LA, Johnston FM, Wong SL. Breast cancer risk and screening in transgender persons: a call for inclusive care. Ann Surgical Oncol. 2022;29:2176–80.

    Article 

    Google Scholar
     

  • D’Andrea S, Pallotti F, Senofonte G, Castellini C, Paoli D, Lombardo F, et al. Polymorphic cytosine-adenine-guanine repeat length of androgen receptor gene and gender incongruence in trans women: a systematic review and meta-analysis of case-control studies. J Sex Med. 2020;17:543–50.

    Article 
    PubMed 

    Google Scholar
     

  • Bostwick DG, Qian J, Civantos F, Roehrborn CG, Montironi R. Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer. 2004;2:228–35.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:479–505.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • McClintock TR, von Landenberg N, Cole AP, Lipsitz SR, Gild P, Sun M, et al. Neoadjuvant androgen deprivation therapy prior to radical prostatectomy: recent trends in utilization and association with postoperative surgical margin status. Ann Surg Oncol. 2019;26:297–305.

    Article 
    PubMed 

    Google Scholar
     

  • Ginsburg KB, Curtis GL, Timar RE, George AK, Cher ML. Delayed radical prostatectomy is not associated with adverse oncologic outcomes: implications for men experiencing surgical delay due to the COVID-19 pandemic. J Urol. 2020;204:720–5.

    Article 
    PubMed 

    Google Scholar
     

  • Berli JU, Knudson G, Fraser L, Tangpricha V, Ettner R, Ettner FM, et al. What surgeons need to know about gender confirmation surgery when providing care for transgender individuals: a review. JAMA Surg. 2017;152:394–400.

    Article 
    PubMed 

    Google Scholar
     

  • Grigsby PW, Russell A, Bruner D, Eifel P, Koh W-J, Spanos W, et al. Late injury of cancer therapy on the female reproductive tract. Int J Radiat Oncol* Biol* Phys. 1995;31:1281–99.

    Article 
    CAS 

    Google Scholar
     

  • Mayadev J, Merrick GS, Reed JR, Butler WM, Galbreath RW, Allen ZA, et al. Permanent prostate brachytherapy in prostate glands <20 cm(3). Int J Radiat Oncol Biol Phys. 2010;76:1450–5.

    Article 
    PubMed 

    Google Scholar
     

  • Chung E, Stenmark MH, Evans C, Narayana V, McLaughlin PW. Greater postimplant swelling in small-volume prostate glands: implications for dosimetry, treatment planning, and operating room technique. Int J Radiat Oncol Biol Phys. 2012;82:1944–8.

    Article 
    PubMed 

    Google Scholar
     

  • Kovtun KA, Wolfsberger L, Niedermayr T, Sugar EN, Graham PL, Murciano-Goroff Y, et al. Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: implications for the use of newer isotopes. Brachytherapy. 2014;13:152–6.

    Article 
    PubMed 

    Google Scholar
     

  • Sanguineti G, Marcenaro M, Franzone P, Tognoni P, Barra S, Vitale V. Is there a “curative” role of radiotherapy for clinically localized hormone refractory prostate cancer? Am J Clin Oncol. 2004;27:264–8.

    Article 
    PubMed 

    Google Scholar
     

  • Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, et al. Addition of androgen-deprivation therapy or brachytherapy boost to external beam radiotherapy for localized prostate cancer: a network meta-analysis of randomized trials. J Clin Oncol. 2020;38:3024–31.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Almazan AN, Keuroghlian AS. Association between gender-affirming surgeries and mental health outcomes. JAMA Surg. 2021;156:611–8.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chen YC, Lin PH, Jou YY, Lin VC. Surgical treatment for urinary incontinence after prostatectomy: a meta-analysis and systematic review. PLoS ONE. 2017;12:e0130867.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Purohit R, Blaivas Jerry G, Kalkan S. V12-03 autologous rectus fascial pubovaginal sling after vaginoplasty: an old trick for a new problem. J Urol. 2019;201:e1205–e1205.

    Article 

    Google Scholar
     

  • Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. NCCN guidelines insights: prostate cancer, version 1.2021: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2021;19:134–43.

    Article 
    CAS 

    Google Scholar
     

  • Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. New Engl J Med. 2022; https://doi.org/10.1056/NEJMoa2119115.

  • Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30:1992–2003.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Markland C. Transexual surgery. Obstet Gynecol Annu. 1975;4:309–30.

  • Sada YH. A Dozen Eggs. J Clin Oncol. 2021;39:3645–6.

  • Molokwu CN, Appelbaum JS, Miksad RA. Detection of prostate cancer following gender reassignment. BJU Int. 2008;101:259; author reply 259–60.